A handful of health-care names are selling at premiums now, but buying opportunities are surfacing, as well.
Novel products will allow drug firms to achieve price premiums on diabetes drugs in the U.S. and at least retain level pricing internationally.
Pfizer Statement on U.S. FDA Approval of Over-the-Counter Nexium® 24HR
Clinigen Group Acquires Oncology Support Therapy SAVENE® (dexrazoxane) from SpePharm AG
UPDATE: Do you take statins? If not, you may have to
Corporate credit spreads are fairly valued--albeit at the tight end of the range that we view as fairly valued.
The corporate bond market will probably struggle to return much above break-even in 2014.
Widening investment-grade credit spreads and rising interest rates lead to losses.
Morningstar StockInvestor editor Matt Coffina explains why he recently purchased Novo Nordisk for StockInvestor's real-money Hare portfolio.
Get our sector-by-sector take on the bond market, plus our five best bond ideas.